Manju George MVSc PhD Rectal Cancer Survivor (@manjuggm) 's Twitter Profile
Manju George MVSc PhD Rectal Cancer Survivor

@manjuggm

Pt Adv, NCI Rectal Anal TF
Mom
Vety Dr
Lifelong learner
Wants to bring pt voice to research clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology

ID: 301419060

linkhttps://coi.asco.org/share/DT2-VJVJ/Manju%20George calendar_today19-05-2011 12:53:17

37,37K Tweet

2,2K Followers

1,1K Following

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

For stage III #coloncancer patients “who want to do everything they can” to be cured & reduce recurrence, what to know to help with decision-making around how much chemo to get? Watch 👇📽️! These are hard decisions, but there’s data from #IDEA to help! #CRCTrialsChat Axel Grothey

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

In this #VideoShort, Dr. Axel Grothey tells us how he decides how much adjuvant chemo his patients need. 📌ctDNA testing may or may not be involved..😜 Watch👇 to learn more. How do you decide the duration of adj chemo for st II & III colon cancer patients in 2024? #CRCTrialsChat

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

What about duration of adjuvant chemo for Stage II #coloncancer patients? 📌What to keep in mind? 📌High risk vs low risk? 📌Two different SOC treatment options! 📌 What if ctDNA (+)? Watch 👇this #videoShort to learn more! #CRCTrialsChat Axel Grothey

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

What's new in 2024 for stage II & III colon cancer that you are excited about and why? Hear from Dr Axel Grothey 👇In this #VideoShort And don't miss the very imp message at the end!! youtu.be/_8tdCYc7XNs #CRCTrialsChat #CRCSM

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

Duration of chemo as part of TNT for stage II & III rectal cancer-- How did we decide on 8 cycles? Watch this #VideoShort to learn more! #LARC #RectalCancer #CRCTrialsChat #CRCSM

#CRCTrialsChat (@crctrialschat) 's Twitter Profile Photo

Please let me know if the #CRCTrialsChat #VideoShorts on the #IDEA trial and things to consider around duration of adjuvant chemo for stage II & III colon cancer was informative for you. #CRCTrialsChat #VideoShorts will be back next month with a new trial. Have a great weekend!

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Bispecific antibodies: advancing precision oncology Trends in Cancer doi.org/10.1016/j.trec… 👉Bispecific antibodies are on the rise with promising data 👏Excellent in depth review ESMO - Eur. Oncology

Bispecific antibodies: advancing precision oncology
<a href="/trendscancer/">Trends in Cancer</a> 
doi.org/10.1016/j.trec…
👉Bispecific antibodies are on the rise with promising data
👏Excellent in depth review
<a href="/myESMO/">ESMO - Eur. Oncology</a>
Tatiana Prowell, MD (@tmprowell) 's Twitter Profile Photo

“EEG abnormalities in #COVID19 patients resemble those observed in early stgs of neurodegenerative diseases, particularly #Alzheimers & related #dementia… neuroinflammation, astrocyte reactivity, hypoxia, & neurovascular injury.”#LongCovid #MedTwitter alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Tatiana Prowell, MD (@tmprowell) 's Twitter Profile Photo

I hope this systematic review serves as a wake-up call to individuals & countries: #COVID19 is not done w/ us. We should both protect ourselves from repeated infections (😷, 💉, & better air quality), but also view this as a clue in understanding & preventing #dementia.

Society of Surgical Oncology (@socsurgonc) 's Twitter Profile Photo

Don't miss this opportunity for SSO members to advance their research initiatives. We have 4 research grants available this year with two made possible through the generous support from Appendix Cancer PMP Research Foundation. Learn more and apply now! surgonc.org/resources/rese…

Don't miss this opportunity for SSO members to advance their research initiatives. We have 4 research grants available this year with two made possible through the generous support from <a href="/acpmpresearch/">Appendix Cancer PMP Research Foundation</a>. 

Learn more and apply now! surgonc.org/resources/rese…
Ramy Sedhom, MD (@ramsedhom) 's Twitter Profile Photo

RCT in Japan showing NO BENEFIT of adding OX to FP + BEV as 1st line treatment in older adults w/ mCRC The authors did a crude vulnerability survey (VES-13) & admit a more thorough GA would be helpful. Still, this helps inform conversation in the clinic

Ramy Sedhom, MD (@ramsedhom) 's Twitter Profile Photo

Another successful study focused on older adults with cancer. In this case, "start low go slow" is a reasonable strategy --no compromise in efficacy --better tolerability --no difference in ability to receive 2nd line therapy Would love to see differences in ability to

Ash Paul (@pash22) 's Twitter Profile Photo

Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer ascopubs.org/doi/10.1200/GO… via Hatice Bölek et al

Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer ascopubs.org/doi/10.1200/GO… via <a href="/hatice_bolek/">Hatice Bölek</a> et al
Michael LaPelusa, MD (@michaellapelusa) 's Twitter Profile Photo

Be sure to check out Dr. Kaysia Ludford present 3-year follow up data in patients with locally advanced dMMR/MSI-H solid tumors treated with pembrolizumab! MD Anderson Cancer Center ESMO - Eur. Oncology #ESMO24

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

🚨Pleased to share the pre-proof version of the editorial commentary just published ESMO - Eur. Oncology flagship journal Annals of Oncology 👉 Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology 🎯💊💉#Oncology #DrugDevelopment

🚨Pleased to share the pre-proof version of the editorial commentary just published <a href="/myESMO/">ESMO - Eur. Oncology</a> flagship journal <a href="/Annals_Oncology/">Annals of Oncology</a> 👉 Optimizing Tomorrow’s Drug Development with Project Optimus: Precision Dosing IS Precision Oncology 
🎯💊💉#Oncology #DrugDevelopment
OncoAlert (@oncoalert) 's Twitter Profile Photo

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Dr Joseph McCollom DO 🇺🇸 Erman Akkus 🇹🇷 Gil Morgan, MD 🇺🇸 1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors

Dear Colleagues, 
The <a href="/OncoAlert/">OncoAlert</a> 🚨Network Presents OUR Picks of  TOP 🔟 GI Abstracts to be Presented at #ESMO24 

This List Curated by: #OncoAlertAF Leads
<a href="/realbowtiedoc/">Dr Joseph McCollom DO</a> 🇺🇸
<a href="/Erman_Akkus/">Erman Akkus</a> 🇹🇷
<a href="/weoncologists/">Gil Morgan, MD</a> 🇺🇸

1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS ❗️An analysis based on MSI status and T4a/b was not performed

Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis 

💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS 

❗️An analysis based on MSI status and T4a/b was not performed
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights 📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer ascopubs.org/doi/10.1200/OP…

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights 

📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer
 ascopubs.org/doi/10.1200/OP…